VUB spin-off PharmaFluidics launches its next generation µPAC™ technology for routine proteomics. PharmaFluidics’ µPAC™ micro-fluidic chips allow to separate and analyze complex biological samples into thousands of components. These can offer better, more standardized workflows to study and monitor the health condition and possible pathologies of the human body, such as cancer, auto immune and metabolic disease patterns, which lead they way to personalized medicine.
Later this week, PharmaFluidics announced that they are looking for a partner to accelerate its growth. This will probably result in selling the company to an investor.